Tag: United

Posted on

United States Women Health Laboratory Testing Markets Report 2022-2030 Featuring Ascension, EKF, Gateway Genomics, Laboratory Corp of America, Myriad Genetics, Natera, Ovia Health, Roche, & Yourgene

United States Women Health Laboratory Testing Markets Report 2022-2030 Featuring Ascension, EKF, Gateway Genomics, Laboratory Corp of America, Myriad Genetics, Natera, Ovia Health, Roche, & Yourgene

DUBLIN, Feb. 20, 2023 /PRNewswire/ — The “U.S. Women Health Laboratory Testing Market – A Region-Wise Analysis: Focus on U.S. Women Health Laboratory Testing Market – Analysis and Forecast, 2022-2030” report has been added to  ResearchAndMarkets.com’s offering. 

 

The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30{35112b74ca1a6bc4decb6697edde3f9edcc1b44915f2ccb9995df8df6b4364bc} during the forecast period 2022-2030.

The market is driven by factors such as the increase in the prevalence of infectious diseases and cancer in women, rising awareness regarding women health-related tests, the rising average maternal age leading to increased risk of fetal chromosomal aneuploidies, and the upsurge in reproductive health problems leading to increased demand for laboratory testing in women.

The U.S. women health laboratory testing market is in the developed phase. The advancements in diagnostic technologies including applications of genetic testing in women’s health and the significant number of mergers and acquisitions of companies to attain a better market share are some of the major opportunities in the U.S. women health laboratory testing market.

How can this report add value to an organization?

The different segment of the report helps the reader understand the different type of laboratory tests/services for women’s health available in the market.

Moreover, the study provides the reader with a detailed understanding of tests/services that fall under the different segments, which are hereditary cancer, carrier screening, prenatal screening, and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology.

Growth/Marketing Strategy: The U.S. women health laboratory testing market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, merger and acquisitions, funding activities, and regulatory and legal approvals.

The favored strategy for the companies has been regulatory and legal activities to strengthen the position of their product in the U.S. market. For instance, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in Late-line Ovarian Cancer.

Recent Developments in the U.S. Women Health Laboratory Testing Market

  • In November 2022, Roche Holdings launched its Cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S. The system can assist in the diagnosis of Infectious diseases, such as HIV, Hepatitis, transplant-associated viral illnesses, and respiratory and STIs.

  • In February 2022, the Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities.

  • In January 2022, Yourgene announced that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc a point-of-care business with accredited laboratory testing capabilities in the U.S.

  • In November 2022, Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.

  • In August 2022, Natera, Inc. announced that the company has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.

Market Segmentation

  • The U.S. women health laboratory testing market (hereditary cancer) is expected to be dominated by the cervical cancer segment.

  • The U.S. women health laboratory testing market (prenatal screening and diagnostic testing) is dominated by the non-invasive prenatal testing segment.

  • The U.S. women health laboratory testing market (reproductive health and infectious diseases) is dominated by the HIV testing segment.

  • The U.S. women health laboratory testing market (by region) is dominated by the South region segment.

Companies Featured

Key Topics Covered:

1 Markets

1.1 U.S. Market Outlook

1.1.1 Product Definition

1.1.2 Inclusion and Exclusion Criteria

1.2 Business Dynamics

1.2.1 Impact Analysis

1.2.2 Business Drivers

1.2.2.1 Increase in the Prevalence of Infectious Diseases and Cancer in Women Leading to Increased Demand for Laboratory Diagnostics

1.2.2.2 Rising Awareness Regarding Women Health-Related Tests

1.2.2.3 Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies

1.2.2.4 Upsurge in Reproductive Health Problems Leading to Increased Demand for Laboratory Testing in Women

1.2.3 Business Restraints

1.2.3.1 Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.

1.2.3.2 Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.

1.2.4 Business Opportunities

1.2.4.1 Advancement in Diagnostic Technologies, including Applications of Genetic Testing in Women’s Health

1.2.4.2 Healthcare Disparities in the Rural Counties of the U.S.

1.2.4.3 Gap in Healthcare for Women of Reproductive Age with Psychological Distress

1.2.4.4 Significant Number of Mergers and Acquisitions by Companies to Attain a Better Market Share

2 U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)

2.1 Overview

2.2 Breast Cancer

2.2.1 Epidemiology

2.2.2 Testing Market

2.2.3 Testing Market (by Region)

2.3 Cervical Cancer

2.4 Ovarian Cancer

3 U.S. Women Health Laboratory Testing Market (by Carrier Screening)

3.1 Overview

3.1.1 Testing Market

3.1.2 Testing Market (by Region)

4 U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)

4.1 Overview

4.2 Non-Invasive Prenatal Testing (NIPT)

4.3 Maternal Serum Screening (MSS)

4.4 Prenatal Diagnostic Testing

5 U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)

5.1 Overview

5.2 Pregnancy and Ovulation Testing

5.3 HPV Testing

5.4 PAP Smear Testing

5.5 HIV Testing

5.6 CT/NG Testing

5.7 Preimplantation Genetic Testing (PGT)

5.8 Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia)

5.9 Herpes Simplex Virus (HSV)

5.10 Hepatitis

5.11 Vaginal Infections

6 U.S. Women Health Laboratory Testing Market (by Obstetrics and Gynaecology)

6.1 Overview

6.1.1 Testing Market (by Region)

For more information about this report visit https://www.researchandmarkets.com/r/eetogi-s-women-health?w=5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/united-states-women-health-laboratory-testing-markets-report-2022-2030-featuring-ascension-ekf-gateway-genomics-laboratory-corp-of-america-myriad-genetics-natera-ovia-health-roche–yourgene-301750614.html

SOURCE Research and Markets

Posted on

Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems — United States, August 2022

Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems — United States, August 2022

COVID-19 Avoidance Approaches

Checking COVID-19 Group Concentrations to guidebook COVID-19 avoidance initiatives. People can use details about the existing amount of COVID-19 impact on their group to make a decision which prevention behaviors to use and when (at all periods or at precise times), dependent on their possess hazard for critical disease and that of users of their residence, their danger tolerance, and setting-particular components. CDC’s COVID-19 Local community Amounts mirror the current result of COVID-19 on communities and discover geographic regions that may possibly encounter improves in intense COVID-19–related outcomes, dependent on hospitalization costs, healthcare facility bed occupancy, and COVID-19 incidence throughout the preceding period*** (1). Prevention suggestions primarily based on COVID-19 Local community Ranges have the explicit plans of lessening medically major ailment and restricting strain on the health and fitness care procedure. At all COVID-19 Group Stages (low, medium, and superior), recommendations emphasize keeping up to date with vaccination, bettering air flow, tests folks who are symptomatic and individuals who have been exposed, and isolating infected individuals. At the medium COVID-19 Local community Stage, advisable tactics contain incorporating protections for persons who are at substantial chance for critical sickness (e.g., use of masks or respirators that deliver a greater stage of wearer defense). At the superior COVID-19 Local community Level, extra tips target on all persons donning masks indoors in community and further escalating defense to populations at significant chance.††† As SARS-CoV-2 continues to flow into, modifications in COVID-19 Group Stages for a jurisdiction aid signal when use of some avoidance procedures need to be discontinued or improved, primarily based on an specific person’s level of threat for significant ailment or that of their home or social contacts. The COVID-19 Community Stages supply a broad framework for public health officers and jurisdictions to use and adapt as necessary dependent on community context by combining local facts to assess the require for public wellbeing interventions.

Nonpharmaceutical interventions. Implementation of multiple avoidance tactics assists secure personal individuals and communities from SARS-CoV-2 exposure and lower risk for medically sizeable ailment and demise by minimizing threat for infection (Table). Implementation of a number of nonpharmaceutical preventive interventions can enhance use of vaccines and therapeutics, especially as COVID-19 Neighborhood Degrees improve and between individuals at superior hazard for serious ailment. CDC’s COVID-19 prevention recommendations no longer differentiate centered on a person’s vaccination status since breakthrough infections arise, although they are typically gentle (16), and people who have experienced COVID-19 but are not vaccinated have some diploma of protection towards severe disease from their previous an infection (17). In addition to techniques recommended at all COVID-19 Local community Amounts, instruction and messaging to enable unique folks have an understanding of their possibility for medically significant sickness complements recommendations for prevention strategies dependent on chance.

Testing for present an infection. Diagnostic tests can detect bacterial infections early so that infected folks can get motion to lower their risk for transmitting virus and acquire treatment method, if clinically indicated, to lower their danger for significant disease and death. All folks need to search for testing for energetic an infection when they are symptomatic or if they have a regarded or suspected publicity to somebody with COVID-19. When looking at no matter whether and in which to put into practice screening testing of asymptomatic folks with no known publicity, public well being officers could consider prioritizing high-risk congregate settings, such as extensive-term treatment facilities, homeless shelters, and correctional amenities, and place of work settings that consist of congregate housing with limited access to healthcare treatment.§§§ In these types of superior-hazard congregate settings, screening screening could complement diagnostic tests of symptomatic persons by determining asymptomatic contaminated individuals (18,19). When applied, screening tests procedures really should involve all individuals, irrespective of vaccination status. Screening testing could possibly not be price-helpful in common community configurations, especially if COVID-19 prevalence is lower (20,21).

Isolation. Symptomatic or infected people must isolate immediately, and infected people should continue to be in isolation for ≥5 times and have on a perfectly-fitting and large-quality mask or respirator if they need to be all-around other folks. Contaminated folks may well conclusion isolation after 5 days, only when they are without a fever for ≥24 hours devoid of the use of medication and all other indicators have enhanced, and they should really continue on to wear a mask or respirator close to other people at home and in public through working day 10¶¶¶ (Figure) (22,23). Folks who have accessibility to antigen tests and who opt for to use tests to establish when they can discontinue masking ought to hold out to get the initially exam until finally at the very least day 6 and they are devoid of a fever for ≥24 several hours without the use of fever-reducing treatment and all other symptoms have improved. Use of two antigen tests with ≥48 hours among assessments delivers much more responsible data simply because of improved exam sensitivity (24). Two consecutive test effects need to be negative for people to discontinue masking. If either examination result is good, individuals really should proceed to don a mask about other people and continue tests every 48 hrs until finally they have two sequential adverse success.****

Running SARS-CoV-2 exposures. CDC now recommends scenario investigation and call tracing only in health and fitness treatment options and sure superior-possibility congregate settings.†††† In all other situations, public overall health endeavours can concentration on case notification and provision of data and means to exposed people about accessibility to testing. Individuals who have had the latest verified or suspected publicity to an contaminated individual should have on a mask for 10 days about other folks when indoors in community and must receive tests ≥5 days right after exposure (or faster, if they are symptomatic), irrespective of their vaccination standing.§§§§ In light-weight of large inhabitants levels of anti–SARS-CoV-2 seroprevalence (7,16), and to limit social and financial impacts, quarantine of uncovered persons is no for a longer time encouraged, no matter of vaccination position.